*Adjusted by hospital group
** Adjusted by hospital group and previous infection status
*** Adjusted VE could not be calculated
Table 3 . Two-dose CoronaVac
effectiveness against symptomatic PCR-confirmed COVID-19 infection for
entire cohort for total study period, and for Delta-predominant period
only, by time since receipt of second vaccine, Azerbaijan, 2021.